AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03705403
Drug: Darleukin
RxNorm normalized name: Darleukin
DrugBank: Darleukin (DB17157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
Trial: NCT00663949
Drug: Captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg captopril tablet q8h
Trial: NCT00663949
Drug: Captopril + Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
Trial: NCT02470442
Drug: Sevoflurane/Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
Trial: NCT02470442
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
Trial: NCT00713622
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
Trial: NCT00713622
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
Trial: NCT00301639
Drug: OROS methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00301639
Drug: methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01785043
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
Trial: NCT04403269
Drug: IgIV
RxNorm normalized name: IGIV
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
Trial: NCT01785043
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
Trial: NCT01341392
Drug: CKD-501
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Trial: NCT01341392
Drug: CKD-501 amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Trial: NCT03857139
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
Trial: NCT05063318
Drug: Lurbinectedin alone
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
Trial: NCT05063318
Drug: Lurbinectedin+Itraconazole co-administration
RxNorm normalized name: lurbinectedin
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
Trial: NCT00160446
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg Tablet, oral Daily for 12 weeks
Trial: NCT00061282
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One retention enema, administered nightly
Trial: NCT00160446
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Tablet, oral Daily for 12 weeks
Trial: NCT00160446
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Tablet, oral Daily for 12 weeks
Trial: NCT02311933
Drug: Endoxifen Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Pipendoxifene (DB05414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03791515
Drug: Calcitonin Gene-Related Peptide
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion.
Trial: NCT03557996
Drug: Silver Diamine Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDF will be applied with a brush
Trial: NCT03557996
Drug: Sodium Fluoride Varnish
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaF will be applied with a brush
Trial: NCT00252044
Drug: Pergolide
RxNorm normalized name: Pergolide
DrugBank: Pergolide (DB01186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02867553
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02674854
Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Trial: NCT02674854
Drug: Latanoprost ophthalmic solution 0.005%
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Trial: NCT00344942
Drug: triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
Trial: NCT00913692
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
Trial: NCT02311933
Drug: Tamoxifen Citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04396860
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01767311
Drug: Lecanemab 2.5 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Trial: NCT01767311
Drug: Lecanemab 5.0 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Trial: NCT01767311
Drug: Lecanemab 10 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
Trial: NCT01767311
Drug: Lecanemab 5.0 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
Trial: NCT01767311
Drug: Lecanemab 10 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
Trial: NCT01767311
Drug: Lecanemab 10 mg/kg
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
Trial: NCT01059929
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Trial: NCT01059929
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Trial: NCT01059929
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
Trial: NCT01111994
Drug: Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
Trial: NCT00251004
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, bis in diem/twice a day (bid)
Trial: NCT02737072
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT00251004
Drug: Cyclosporine A (CsA)
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA dose adjustments were based on CsA trough levels (C0).
Trial: NCT00251004
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
Trial: NCT02360124
Drug: silver diammine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application of the SDF solution onto tooth root surfaces
Trial: NCT04056897
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
Trial: NCT00266877
Drug: HKI-272
RxNorm normalized name: HKI-357
DrugBank: HKI-357 (DB13002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Trial: NCT02508298
Drug: Indocyanine Green Retention test
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As decribed in arm descriptions
Trial: NCT00427401
Drug: PF-00915275
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01174238
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
Trial: NCT01174238
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
Trial: NCT01174238
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
Trial: NCT02456662
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
Trial: NCT04489888
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
Trial: NCT04489888
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
Trial: NCT04489888
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Trial: NCT04241185
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
Trial: NCT04241185
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Trial: NCT04066764
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
Trial: NCT04066764
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
Trial: NCT04241185
Drug: Mitomycin C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Trial: NCT04241185
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Trial: NCT04241185
Drug: Placebo to Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
Trial: NCT04066764
Drug: Nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Trial: NCT01847807
Drug: high dose astagalus
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03181763
Drug: Midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg midomafetamine HCl on their second visit
Trial: NCT04382404
Drug: Sofosbuvir-Velpatasvir Drug Combination
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
Trial: NCT03149848
Drug: Cabotegravir
RxNorm normalized name: cabotegravir
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
Trial: NCT03149848
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
Trial: NCT01244490
Drug: Extended-release Guanfacine Hydrochloride
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
Trial: NCT01244490
Drug: Atomoxetine Hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
Trial: NCT02763969
Drug: BMS-986202
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02763969
Drug: Interferon alpha-2a recombinant
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02763969
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02763969
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02562118
Drug: Lenvatinib + Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
Trial: NCT03587363
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
Trial: NCT01466543
Drug: Zydena (Udenafil)
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zydena (Udenafil) 100 mg, one time
Trial: NCT02960893
Drug: Troriluzole
RxNorm normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
Trial: NCT02960893
Drug: Troriluzole
RxNorm normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Trial: NCT02795780
Drug: Flortaucipir F18
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 megabecquerel (MBq) IV single-dose
Trial: NCT00954252
Drug: CHF 5074
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x, oral capsule, single dose
Trial: NCT00954252
Drug: CHF 5074
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x, oral capsule, single dose
Trial: NCT00954252
Drug: CHF 5074
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x, oral capsule, single dose
Trial: NCT00954252
Drug: CHF 5074
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8x, oral capsule, single dose